Adicet Bio Inc (ACET) Quote

ACET under $2

ACET under $2

ACET new 52 week low

ACET..............................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783

HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target


HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We plan to initiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta CAR T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune program to address additional indications beyond lupus nephritis. We look forward to providing a comprehensive update on our autoimmune program to investors in the near term.”

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

ACET....................................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783

ACET new 52 week low

ACET new 52 week

ACET new 52 week low

Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting

Durability was always the big question for $ACET. Yesterday's dataset vs #ASH22 above https://t.co/PNIL1N2eUF— Jacob Plieth (@JacobPlieth) June 27, 2023

No sell off...guess I bet wrong

Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned

It was weird....I think the MMs drop this at open to begin the sell off today.

whats weird is the rally after the offering


this market is upside down

topsy turvey

Bought puts today anticipating an offering and there it is.

13.20 low start

ACET

14.20 in AH. Nice day for the clinical FDA phase I trial results.

thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca

Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.

Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.